RecruitingNot ApplicableNCT05889247

Circulating Tumor DNA Guided Treatment Monitoring in Advanced Lung Cancer

Circulating Tumor DNA Guided Treatment Monitoring in Advanced Lung Cancer - a Randomized Interventional Study

Sponsor

Zealand University Hospital

Enrollment

350 participants

Start Date

Jul 28, 2023

Study Type

INTERVENTIONAL

Conditions

Non-small Cell Lung Cancer Metastatic

Summary

The study is a prospective randomized interventional study including patients with advanced non-small cell lung cancer, receiving immunotherapy, with the aim of optimizing treatment monitoring. The study aims to investigate the clinical utility of liquid biopsy monitoring in order to reduce the numbers of inefficient treatments and needless toxicity - and to explore the cost-effectiveness and cost-utility of introducing liquid biopsy monitoring in daily clinical practice.

Eligibility

Plain Language Summary

Simplified for easier understanding

This study is testing whether tracking tiny fragments of tumor DNA in the blood can help doctors better monitor how well immunotherapy is working for people with advanced lung cancer. **You may be eligible if...** - You have been newly diagnosed with non-small cell lung cancer (NSCLC) that is advanced or has spread locally - Your cancer cannot be cured with current treatments - You are 18 or older and in good general health (able to do most daily activities) - You are eligible to start first-line immunotherapy (a single-drug immune treatment) - Your cancer can be measured on scans **You may NOT be eligible if...** - Your cancer has certain gene mutations (EGFR, ALK, or ROS-1) that have targeted treatments - You have another active cancer Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERCirculating tumor DNA treatment monitoring

A comparison of treatment monitoring by circulating tumor DNA and CT scans (standard) in patients with newly diagnosed advanced Non-Small Cell Lung Cancer (NSCLC)